Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Boosted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 17.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 36,636 shares of the pharmaceutical company’s stock after acquiring an additional 5,572 shares during the period. Daiwa Securities Group Inc.’s holdings in Vertex Pharmaceuticals were worth $12,739,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of VRTX. Cooper Financial Group boosted its stake in Vertex Pharmaceuticals by 1.0% during the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock valued at $1,050,000 after buying an additional 29 shares in the last quarter. Paradigm Financial Partners LLC lifted its holdings in Vertex Pharmaceuticals by 2.1% in the 2nd quarter. Paradigm Financial Partners LLC now owns 1,446 shares of the pharmaceutical company’s stock valued at $509,000 after acquiring an additional 30 shares during the last quarter. Grandfield & Dodd LLC boosted its position in shares of Vertex Pharmaceuticals by 0.3% during the 2nd quarter. Grandfield & Dodd LLC now owns 9,018 shares of the pharmaceutical company’s stock valued at $3,174,000 after purchasing an additional 30 shares in the last quarter. West Family Investments Inc. grew its stake in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. West Family Investments Inc. now owns 2,494 shares of the pharmaceutical company’s stock worth $878,000 after purchasing an additional 30 shares during the last quarter. Finally, FRG Family Wealth Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 0.9% in the 3rd quarter. FRG Family Wealth Advisors LLC now owns 3,292 shares of the pharmaceutical company’s stock worth $1,145,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 90.77% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.9 %

Shares of Vertex Pharmaceuticals stock opened at $433.76 on Thursday. The firm has a market cap of $111.77 billion, a price-to-earnings ratio of 32.54, a P/E/G ratio of 2.80 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.08 and a quick ratio of 3.89. Vertex Pharmaceuticals Incorporated has a 52-week low of $283.60 and a 52-week high of $439.77. The stock has a 50-day simple moving average of $386.04 and a 200-day simple moving average of $365.43.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings results on Monday, November 6th. The pharmaceutical company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $3.53 by $0.55. Vertex Pharmaceuticals had a return on equity of 22.79% and a net margin of 35.94%. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the firm earned $3.62 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 13.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on VRTX shares. Truist Financial restated a “buy” rating and set a $456.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, October 4th. Barclays raised their price objective on Vertex Pharmaceuticals from $408.00 to $415.00 and gave the stock an “overweight” rating in a research note on Monday, December 11th. Stifel Nicolaus reissued a “hold” rating and set a $373.00 price objective on shares of Vertex Pharmaceuticals in a research note on Wednesday, November 22nd. StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th. Finally, Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $359.00 to $364.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $381.86.

View Our Latest Stock Report on VRTX

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 11,250 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $385.00, for a total value of $4,331,250.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at $15,400,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the transaction, the chairman now owns 2,423 shares of the company’s stock, valued at approximately $1,015,406.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce I. Sachs sold 11,250 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $385.00, for a total transaction of $4,331,250.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $15,400,000. The disclosure for this sale can be found here. Insiders sold 23,549 shares of company stock valued at $9,128,531 over the last quarter. Insiders own 0.40% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.